Assessing the future of diffuse optical imaging technologies for breast cancer management
Assessing the future of diffuse optical imaging technologies for breast cancer management
复制标题
DOI：
10.1118/1.2919078
复制
发表时间：
2008-06-01
期刊：
影响因子：
3.8
通讯作者：
Cerussi, Albert E.
中科院分区：
文献类型：
--
作者：
Tromberg, Bruce J.;Pogue, Brian W.;Cerussi, Albert E.
扩散光学成像（DOI）是一种非侵入性的光学技术，采用近红外（NIR）光定量表征厚组织的光学特性。尽管近红外方法在近80年前首次应用于乳房透照（也称为透照术），但采用时域或频域光子迁移技术的定量DOI方法最近才用于乳房成像（即，自1990年代中期以来）。在这篇综述中，最先进的DOI乳腺癌的概述和多机构网络的光学成像转化研究（NTROI），已形成的国家癌症研究所推进扩散光谱和成像（DOSI）或改善乳腺癌的检测和临床管理的目的。DOSI在近红外光谱和时间信号域中采用宽带技术，以便将吸收与散射分离，并基于吸收或荧光对比度量化多个分子探针的摄取。通过将DOSI的功能信息与分别提供结构信息或血管流动信息的X射线乳腺摄影术和磁共振成像（MRI）进行整合和共配准来提供数据中的额外维度。影响DOSI性能的因素，如内在和外在的对比机制，生化成分的定量，图像形成/可视化，以及多模态共配准正在进行的研究NTROI网站。其中一个目标是开发标准化的DOSI平台，可以作为独立设备使用，也可以与MRI、乳腺X射线摄影或超声结合使用。这种基础广泛的多学科努力有望提供有关乳腺疾病起源的新见解和解决乳腺癌几个关键挑战的实用方法，包括：检测乳腺摄影致密组织中的疾病，区分恶性和良性病变，以及了解新辅助化疗的影响。(C)2008年美国医学物理学家协会。
Diffuse optical imaging (DOI) is a noninvasive optical technique that employs near-infrared (NIR) light to quantitatively characterize the optical properties of thick tissues. Although NIR methods were first applied to breast transillumination (also called diaphanography) nearly 80 years ago, quantitative DOI methods employing time-or frequency-domain photon migration technologies have only recently been used for breast imaging (i.e., since the mid-1990s). In this review, the state of the art in DOI for breast cancer is outlined and a multi-institutional Network for Translational Research in Optical Imaging (NTROI) is described, which has been formed by the National Cancer Institute to advance diffuse optical spectroscopy and imaging (DOSI) f or the purpose of improving breast cancer detection and clinical management. DOSI employs broadband technology both in near-infrared spectral and temporal signal domains in order to separate absorption from scattering and quantify uptake of multiple molecular probes based on absorption or fluorescence contrast. Additional dimensionality in the data is provided by integrating and co-registering the functional information of DOSI with x-ray mammography and magnetic resonance imaging (MRI), which provide structural information or vascular flow information, respectively. Factors affecting DOSI performance, such as intrinsic and extrinsic contrast mechanisms, quantitation of biochemical components, image formation/visualization, and multimodality co-registration are under investigation in the ongoing research NTROI sites. One of the goals is to develop standardized DOSI platforms that can be used as stand-alone devices or in conjunction with MRI, mammography, or ultrasound. This broad-based, multidisciplinary effort is expected to provide new insight regarding the origins of breast disease and practical approaches for addressing several key challenges in breast cancer, including: Detecting disease in mammographically dense tissue, distinguishing between malignant and benign lesions, and understanding the impact of neoadjuvant chemotherapies. (C) 2008 American Association of Physicists in Medicine.